Mirum Pharmaceuticals, a late-stage biotech developing therapies for rare cholestatic liver diseases, raised $75 million by offering 5.0 million shares at $15, the midpoint of the $14 to $16 range. Insiders had indicated on purchasing $35 million of the IPO (47% of the deal).
Mirum Pharmaceuticals plans to list on the Nasdaq under the symbol MIRM. Citi, Evercore ISI and Guggenheim Securities acted as lead managers on the deal.
